Company Profile
Year Established :
1972
Total Assets(USD) :
More than 99,999,999
Total Number of Staff :
more than 1000
Main Competitive Advantages :
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted
R&D Capacity :
OEM,ODM,Own Brand
Main Sales Markets :
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Beijing Scrianen Pharmaceutical Co., Ltd., formerly known as Beijing Medical University Experimental Pharmaceutical Factory established in October 1970, was restructured into a limited liability company in November 2001. After more than 50 years of unremitting efforts, it has now developed into a comprehensive pharmaceutical enterprise with research and development, production, and sales capabilities, and is a national high-tech enterprise.
Beijing Scrianen Pharmaceutical Cangzhou Branch is the raw material production base of Beijing Scrianen Pharmaceutical, located in the western area of Lingang Economic and Technological Development Zone in Hebei Province, with a total area of about 42 acres. At present, there are three synthesis workshops for general chemistry, anti-tumor, and hormones, with an estimated annual production capacity of up to 50 tons.
The company relies on the strong software and hardware capabilities of the R&D center of the group company to carry out research and development of new products and technical improvement of old products while producing raw materials; We have an excellent team with rich management experience and exquisite professional skills in pharmaceutical synthesis chemistry, and multiple independent production lines that are internationally first-class; With various sizes of synthetic reactors ranging from 50L to 3000L, we are committed to providing integrated services such as production and control of chemical drugs and pharmaceutical intermediates, optimization of pilot processes, and customized contract production for large pharmaceutical companies, small and medium-sized pharmaceutical or biopharmaceutical technology research and development companies both domestically and internationally.